Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors.
about
Taxanes in the elderly patient with metastatic breast cancerCardiac risk in the treatment of breast cancer: assessment and management.The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis.A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients.Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.Global longitudinal strain: a useful everyday measurement?"Targeted" Chemotherapy for Esophageal CancerSystems biology approaches to adverse drug effects: the example of cardio-oncology.Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.Therapeutic potentials of short interfering RNAs.Echocardiographic Assessment of Cardiotoxic Effects of Cancer Therapy.Delivering safer immunotherapies for cancer.Speckle-tracking global longitudinal strain as an early predictor of cardiotoxicity in breast carcinoma.Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational StudyAntioxidant Therapeutic Strategies for Cardiovascular Conditions Associated with Oxidative Stress.Trastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancer.Factors for time to trastuzumab-induced cardiotoxicity in breast cancer patients.Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.Can a nanoparticle that mimics Salmonella effectively combat tumor chemotherapy resistance?Investigation of the role of DNA methylation in the expression of ERBB2 in human myocardium.Cardiovascular Toxicities of Small Molecule Tyrosine Kinase Inhibitors: An Opportunity for Systems-Based Approaches.Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study.Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer.Antibody-Drug Conjugates for Cancer Therapy.
P2860
Q26785458-123C469A-D76E-4F9A-85FD-7D56AF9CD5EAQ28081385-76C35CCA-B293-42AE-B928-D1176B26BB54Q35948882-F614B8E9-DCBA-4343-848C-2C3DA6EC523AQ36153113-5471B148-F237-4BDC-A289-B0E57DB77C6CQ36884357-9B2E5CA3-A298-491D-9452-489DE9C83502Q37361224-D187B617-B419-4C68-A7A3-A8FE66D121CDQ37734452-2FB4F5A3-9581-4387-BA19-54765D86B968Q38606067-12D9D163-F4D4-48DD-9C79-1D229D38C306Q38639456-2F7C210D-7D7B-472E-A4BF-8548C4417F03Q38645080-0501A7FD-E7A1-444E-9CE3-524D736E90F2Q38938410-D72EA8C2-384F-4F91-A417-B260C60770CAQ39330984-3845335B-DE9D-49CF-9EE2-FA68160A09E5Q39962402-722C0BDE-18B0-4FB2-B639-575E09D274BBQ41439263-9F39B8BA-1ADD-4C6E-ADE6-D797A739BA92Q42368225-A2CC4CB9-6C5E-45B3-8085-54B8692368F3Q47863782-AD2ED19A-5A19-4058-B8F6-25EA62AC786AQ48257610-2126AE0E-0A70-4786-B71E-3F252887715DQ49136273-6485CA87-38BE-4D7A-9D88-8FB6CE1EC4A3Q49953744-F4C6BBCF-4C9F-4275-BE66-3076E0C71FB9Q50875570-E4721855-915D-4594-8711-CCBCF76D5908Q51348764-3DB23BEB-6B9F-4E62-B05C-2F8E8DFB0FFAQ51715669-94303AD4-44C8-4E6E-B13C-B9FA3F3382FAQ52582168-3526ABD5-7A33-4F13-8F71-FAE1B98AC011Q53739135-FA79892E-1C31-4391-825E-8C30029B5D2E
P2860
Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Cardiovascular toxicity associ ...... acteristics, and risk factors.
@ast
Cardiovascular toxicity associ ...... acteristics, and risk factors.
@en
type
label
Cardiovascular toxicity associ ...... acteristics, and risk factors.
@ast
Cardiovascular toxicity associ ...... acteristics, and risk factors.
@en
prefLabel
Cardiovascular toxicity associ ...... acteristics, and risk factors.
@ast
Cardiovascular toxicity associ ...... acteristics, and risk factors.
@en
P2093
P2860
P356
P1476
Cardiovascular toxicity associ ...... acteristics, and risk factors.
@en
P2093
Adedayo A Onitilo
Jessica M Engel
Rachel V Stankowski
P2860
P304
P356
10.1177/2042098614529603
P577
2014-08-01T00:00:00Z